Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Open Label Study to Evaluate the Pharmacodynamics of Nivolumab in Combination with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase II, Multicenter, Open Label Study to Evaluate the Pharmacodynamics of Nivolumab in Combination with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer; Brain cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Biomarker; Pharmacodynamics
  • Acronyms IPINIVO
  • Sponsors Agenus

Most Recent Events

  • 12 Apr 2018 Status changed from active, no longer recruiting to completed.
  • 02 Nov 2017 Status changed from recruiting to active, no longer recruiting.
  • 19 Aug 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top